Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung

A southwest oncology group study

Robert B Livingston, L. Helibrun, D. Lehane, J. J. Costanzi, R. Bottomley, R. L. Palmer, W. J. Stuckey, B. Hoogstraten

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The Southwest Oncology Group carried out a comparative study of two combination chemotherapy regimens in 231 patients with extensive squamous carcinoma of the lung. One regimen consisted of bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON). The other involved mechlorethamine, adriamycin, and CCNU (NAC) in the same dose and schedule but with the deletion of vincristine and bleomycin. The response rate was 21% for BACON and 16% for NAC. The median survival time (MST) was 16 weeks for all patients receiving each regimen. Pretreatment performance status (PS) was significantly related to the response rates: these were 28% for BACON and 23% for NAC among fully ambulatory patients (PS, 8-10) versus 15% for BACON an 10% for NAC among those with a lesser PS (P <0.05). Survival was also influenced by PS; the MST was 28 weeks for PSs 8-10 with either regimen compared to an overall MST of 11.5 weeks for patients with PSs 5-7 and 2.8 weeks for PSs 1-4. The toxicity of the two regimens was comparable with a 4% incidence of treatment-related deaths. An additional 10% of the patients were hospitalized because of life-threatening but reversible toxic effects. The only patients for whom there may be an improvement in MST over that expected from supportive care alone are those with PSs 8-10. Patients who demonstrated response or improvement regardless of PS, had a significantly longer MST: 39.5 versus 11.2 weeks for those who did not respond (P=0.001).

Original languageEnglish (US)
Pages (from-to)1623-1629
Number of pages7
JournalCancer Treatment Reports
Volume61
Issue number9
StatePublished - 1977
Externally publishedYes

Fingerprint

Combination Drug Therapy
Squamous Cell Carcinoma
Lung
Survival
Lomustine
Mechlorethamine
Bleomycin
Vincristine
Doxorubicin
Poisons
Appointments and Schedules
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Livingston, R. B., Helibrun, L., Lehane, D., Costanzi, J. J., Bottomley, R., Palmer, R. L., ... Hoogstraten, B. (1977). Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: A southwest oncology group study. Cancer Treatment Reports, 61(9), 1623-1629.

Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung : A southwest oncology group study. / Livingston, Robert B; Helibrun, L.; Lehane, D.; Costanzi, J. J.; Bottomley, R.; Palmer, R. L.; Stuckey, W. J.; Hoogstraten, B.

In: Cancer Treatment Reports, Vol. 61, No. 9, 1977, p. 1623-1629.

Research output: Contribution to journalArticle

Livingston, RB, Helibrun, L, Lehane, D, Costanzi, JJ, Bottomley, R, Palmer, RL, Stuckey, WJ & Hoogstraten, B 1977, 'Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: A southwest oncology group study', Cancer Treatment Reports, vol. 61, no. 9, pp. 1623-1629.
Livingston, Robert B ; Helibrun, L. ; Lehane, D. ; Costanzi, J. J. ; Bottomley, R. ; Palmer, R. L. ; Stuckey, W. J. ; Hoogstraten, B. / Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung : A southwest oncology group study. In: Cancer Treatment Reports. 1977 ; Vol. 61, No. 9. pp. 1623-1629.
@article{9c54595090bb437782ccb4801e26fe16,
title = "Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: A southwest oncology group study",
abstract = "The Southwest Oncology Group carried out a comparative study of two combination chemotherapy regimens in 231 patients with extensive squamous carcinoma of the lung. One regimen consisted of bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON). The other involved mechlorethamine, adriamycin, and CCNU (NAC) in the same dose and schedule but with the deletion of vincristine and bleomycin. The response rate was 21{\%} for BACON and 16{\%} for NAC. The median survival time (MST) was 16 weeks for all patients receiving each regimen. Pretreatment performance status (PS) was significantly related to the response rates: these were 28{\%} for BACON and 23{\%} for NAC among fully ambulatory patients (PS, 8-10) versus 15{\%} for BACON an 10{\%} for NAC among those with a lesser PS (P <0.05). Survival was also influenced by PS; the MST was 28 weeks for PSs 8-10 with either regimen compared to an overall MST of 11.5 weeks for patients with PSs 5-7 and 2.8 weeks for PSs 1-4. The toxicity of the two regimens was comparable with a 4{\%} incidence of treatment-related deaths. An additional 10{\%} of the patients were hospitalized because of life-threatening but reversible toxic effects. The only patients for whom there may be an improvement in MST over that expected from supportive care alone are those with PSs 8-10. Patients who demonstrated response or improvement regardless of PS, had a significantly longer MST: 39.5 versus 11.2 weeks for those who did not respond (P=0.001).",
author = "Livingston, {Robert B} and L. Helibrun and D. Lehane and Costanzi, {J. J.} and R. Bottomley and Palmer, {R. L.} and Stuckey, {W. J.} and B. Hoogstraten",
year = "1977",
language = "English (US)",
volume = "61",
pages = "1623--1629",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung

T2 - A southwest oncology group study

AU - Livingston, Robert B

AU - Helibrun, L.

AU - Lehane, D.

AU - Costanzi, J. J.

AU - Bottomley, R.

AU - Palmer, R. L.

AU - Stuckey, W. J.

AU - Hoogstraten, B.

PY - 1977

Y1 - 1977

N2 - The Southwest Oncology Group carried out a comparative study of two combination chemotherapy regimens in 231 patients with extensive squamous carcinoma of the lung. One regimen consisted of bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON). The other involved mechlorethamine, adriamycin, and CCNU (NAC) in the same dose and schedule but with the deletion of vincristine and bleomycin. The response rate was 21% for BACON and 16% for NAC. The median survival time (MST) was 16 weeks for all patients receiving each regimen. Pretreatment performance status (PS) was significantly related to the response rates: these were 28% for BACON and 23% for NAC among fully ambulatory patients (PS, 8-10) versus 15% for BACON an 10% for NAC among those with a lesser PS (P <0.05). Survival was also influenced by PS; the MST was 28 weeks for PSs 8-10 with either regimen compared to an overall MST of 11.5 weeks for patients with PSs 5-7 and 2.8 weeks for PSs 1-4. The toxicity of the two regimens was comparable with a 4% incidence of treatment-related deaths. An additional 10% of the patients were hospitalized because of life-threatening but reversible toxic effects. The only patients for whom there may be an improvement in MST over that expected from supportive care alone are those with PSs 8-10. Patients who demonstrated response or improvement regardless of PS, had a significantly longer MST: 39.5 versus 11.2 weeks for those who did not respond (P=0.001).

AB - The Southwest Oncology Group carried out a comparative study of two combination chemotherapy regimens in 231 patients with extensive squamous carcinoma of the lung. One regimen consisted of bleomycin, adriamycin, CCNU, vincristine, and mechlorethamine (BACON). The other involved mechlorethamine, adriamycin, and CCNU (NAC) in the same dose and schedule but with the deletion of vincristine and bleomycin. The response rate was 21% for BACON and 16% for NAC. The median survival time (MST) was 16 weeks for all patients receiving each regimen. Pretreatment performance status (PS) was significantly related to the response rates: these were 28% for BACON and 23% for NAC among fully ambulatory patients (PS, 8-10) versus 15% for BACON an 10% for NAC among those with a lesser PS (P <0.05). Survival was also influenced by PS; the MST was 28 weeks for PSs 8-10 with either regimen compared to an overall MST of 11.5 weeks for patients with PSs 5-7 and 2.8 weeks for PSs 1-4. The toxicity of the two regimens was comparable with a 4% incidence of treatment-related deaths. An additional 10% of the patients were hospitalized because of life-threatening but reversible toxic effects. The only patients for whom there may be an improvement in MST over that expected from supportive care alone are those with PSs 8-10. Patients who demonstrated response or improvement regardless of PS, had a significantly longer MST: 39.5 versus 11.2 weeks for those who did not respond (P=0.001).

UR - http://www.scopus.com/inward/record.url?scp=0017573649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017573649&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 1623

EP - 1629

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -